US Pharma MarketingFDA approves Revolution Medicines
FDA approves Revolution Medicines Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's negotiation power FDA policy and drug…
The FDA gave the green light to a highly anticipated pancreatic cancer treatment that has altered the prospects for patients facing the deadly disease.
The agency on Wednesday approved Revolution Medicines’ daraxonrasib for second-line pancreatic ...
Source: Endpoints News